Xcovery to Present at 8th Annual Biotech Showcase™

NEEDHAM, Mass. and PALM BEACH GARDENS, Fla., Jan. 5, 2016 /PRNewswire/ -- Xcovery, a developer of targeted therapeutics for cancer, today announced it will present a company update during the eighth annual Biotech Showcase™ at the Parc 55 Hilton hotel in San Francisco.

Xcovery CEO Michael D. Webb will present a company update on Jan. 12, 2016, at 10:15 a.m. PST in the Davidson room.

Xcovery's lead asset is X-396, a small molecule, anaplastic lymphoma kinase (ALK) inhibitor. It is being studied in the Xalt2 Study, a phase 2 trial for the treatment of ALK-positive non-small cell lung cancer (NSCLC). X-396 also is being studied to treat patients with lymphoma and neuroblastoma. X-396 has been validated in potency and selectivity assays that demonstrate it is more selective and up to 10 times more potent than competitive ALK inhibitors tested. The Xalt2 Study is currently enrolling patients. To learn more, visit: www.xalt2study.com.

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.

About Non-Small Cell Lung Cancer and ALK
Lung cancer is the second most common type of cancer identified in the United States with an estimated 221,000 new diagnoses expected in 2015.  Non-small cell lung cancer is the most common type of lung cancer, accounting for an estimated 85-90% of the lung cancer cases.

The anaplastic lymphoma kinase (ALK) gene is located on chromosome 2 and rearrangement of the ALK gene can lead to its activation or expression therefore increasing a person's chance of certain types of cancer, including NSCLC.  Between three and seven percent of patients with NSCLC have the ALK rearrangement making this a molecular target warranting investigation for NSCLC patients.

About Xcovery
Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors.  Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors.  For more information, visit www.xcovery.com

Forward-Looking Statements
This press release contains forward-looking statements that are based on company management's current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.

Corporate Contact:
Teri Swift
Tyrogenex Corporate Communications
(561) 406-9705
[email protected]

Logo - http://photos.prnewswire.com/prnh/20151228/318197LOGO

SOURCE Xcovery

Related Links

http://www.xcovery.com